{
    "id": 60079,
    "name": "Her2-receptor positive breast cancer",
    "source": "DOID",
    "definition": "A breast cancer that is characterized by the presence of Her2 receptors. [url:https\\://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-hormone-receptor-status.html, url:https\\://www.sciencedirect.com/science/article/pii/S1470204511703369]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0060079",
    "evidence": [
        {
            "id": 286,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on trastuzumab-based therapy (PMID: 24470511).",
            "molecularProfile": {
                "id": 1409,
                "profileName": "ERBB2 pos PIK3CA act mut"
            },
            "therapy": {
                "id": 1417,
                "therapyName": "Buparlisib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 196,
                    "pubMedId": 24470511,
                    "title": "Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24470511"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 288,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated in patients with ERBB2 (HER2)-positive advanced or metastatic breast cancer that had progressed on Herceptin (trastuzumab) (PMID: 24470511).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1417,
                "therapyName": "Buparlisib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 196,
                    "pubMedId": 24470511,
                    "title": "Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24470511"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 874,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PTEN loss demonstrated a decreased median progression-free survival of 6.0 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).",
            "molecularProfile": {
                "id": 1410,
                "profileName": "ERBB2 pos PTEN loss"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 224,
                    "pubMedId": 21676217,
                    "title": "PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21676217"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 875,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation due to PTEN loss and/or PIK3CA activating mutation demonstrated a decreased median progression-free survival of 4.5 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).",
            "molecularProfile": {
                "id": 1409,
                "profileName": "ERBB2 pos PIK3CA act mut"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 224,
                    "pubMedId": 21676217,
                    "title": "PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21676217"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6664,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).",
            "molecularProfile": {
                "id": 1409,
                "profileName": "ERBB2 pos PIK3CA act mut"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 213,
                    "pubMedId": 17936563,
                    "title": "A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17936563"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17456,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) combined with a taxane, such as Taxotere (docetaxel) or Taxol (paclitaxel), is included in guidelines as neoadjuvant therapy for ERBB2 (HER2)-positive patients with early breast cancer or as first-line therapy for ERBB2 (HER2)-positive patients with advanced breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15502,
                    "pubMedId": 31236598,
                    "title": "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236598"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17481,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) is FDA approved as an adjuvant treatment for ERBB2 (HER2)-overexpressing (or amplification) breast cancer patients and for metastatic ERBB2 (HER2)-overexpressing (or amplification) breast cancer patients as indicated by an FDA approved companion diagnostic (FDA.gov).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15509,
                    "pubMedId": null,
                    "title": "Herceptin (trastuzumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103792"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 892,
            "approvalStatus": "Clinical Study - Meta-analysis",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a meta-analysis, breast cancer patients with >12 copies of ERBB2 (HER2) had a better response to Herceptin (trastuzumab) than patients with 6-12 copies of ERBB2 (HER2) (PMID: 24691421).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 892,
                    "pubMedId": 24691421,
                    "title": "Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24691421"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 896,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Nerlynx (neratinib) demonstrated safety and efficacy as a monotherapy in patients with ERBB2 (HER2)-positive breast cancer (PMID: 23953056).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 581,
                    "pubMedId": 23953056,
                    "title": "A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23953056"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 897,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Margetuximab (MGAH22) treatment resulted in tumor reduction in 78% (18/23) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 28119295).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 808,
                "therapyName": "MGAH22",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8461,
                    "pubMedId": 28119295,
                    "title": "First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28119295"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 899,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, MM-302 demonstrated safety in patients with ERBB2 (HER2) positive breast cancer (Cancer Res 2012;72(24 Suppl):Abstract nr P5-18-09)",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1401,
                "therapyName": "MM-302",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 583,
                    "pubMedId": null,
                    "title": "A Phase I Study of MM-302, a HER2-targeted Liposomal Doxorubicin, in Patients with Advanced, HER2- Positive Breast Cancer",
                    "url": "http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P5-18-09"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 906,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Sutent (sunitinib), in combination with Herceptin (trastuzumab), demonstrated safety and efficacy in ERBB2 (HER2) positive advanced breast cancer patients (PMID: 24606768).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1658,
                "therapyName": "Sunitinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 591,
                    "pubMedId": 24606768,
                    "title": "Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24606768"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 909,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase II clinical trials, ERBB2 (HER2) vaccines demonstrated safety and some efficacy in the adjuvant setting in ERBB2 (HER2)-positive breast cancer patients (PMID: 23585514).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1404,
                "therapyName": "HER2 Vaccine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 595,
                    "pubMedId": 23585514,
                    "title": "Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23585514"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 937,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, the combination of TS-1 (S-1) and Herceptin (trastuzumab) demonstrated safety and efficacy in patients with ERBB2 (HER2)-positive metastatic breast cancer, with an overall response rate of 53.6% (15/28), and a clinical benefit rate of 75.0% (21/28) (PMID: 24982373).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1408,
                "therapyName": "Oxaliplatin + Trastuzumab + TS-1",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 984,
                    "pubMedId": 24982373,
                    "title": "Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24982373"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 938,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase II clinical trials, the combination of Xeloda (capecitabine) and Herceptin (trastuzumab) demonstrated efficacy with a manageable toxicity profile in heavily pretreated patients with ERBB2 (HER2)-positive advanced breast cancer and earlier Herceptin (trastuzumab) exposure (PMID: 17679724).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1409,
                "therapyName": "Capecitabine + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 613,
                    "pubMedId": 17679724,
                    "title": "Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17679724"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 945,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (BOLERO-3), the combination of Afinitor (everolimus), Herceptin (trastuzumab), and Navelbine (vinorelbine) increased progression-free survival in patients with Herceptin (trastuzumab)-resistant, ERBB2 (HER2)-positive, advanced breast cancer who had prior taxane treatment (PMID: 24742739; NCT01007942).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1411,
                "therapyName": "Everolimus + Trastuzumab + Vinorelbine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 619,
                    "pubMedId": 24742739,
                    "title": "Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24742739"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 946,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive breast cancer cells in culture (PMID: 24300914).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1412,
                "therapyName": "Oxaliplatin + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 620,
                    "pubMedId": 24300914,
                    "title": "Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24300914"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 953,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cells expressing ERBB2 (HER2) T798M were resistant to Tykerb (lapatinib) in both culture and xenograft models (PMID: 23948973).",
            "molecularProfile": {
                "id": 1572,
                "profileName": "ERBB2 T798M"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 624,
                    "pubMedId": 23948973,
                    "title": "Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23948973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 966,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mouse breast cancer models over expressing ERBB2 (HER2) and expressing PIK3CA H1047R were resistant to Herceptin (trastuzumab) (PMID: 23940356).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 240,
                    "pubMedId": 23940356,
                    "title": "Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23940356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 967,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Buparlisib (BKM120) resulted in decreased tumor growth, but not tumor regression, in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R (PMID: 23940356).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 1178,
                "therapyName": "Bevacizumab + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 240,
                    "pubMedId": 23940356,
                    "title": "Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23940356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 968,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Herceptin (trastuzumab) and Buparlisib (BKM120) inhibited tumor growth in mouse ERBB2 (HER2)-over expressing breast cancer models expressing PIK3CA H1047R, with moderate efficacy over Buparlisib (BKM120) alone (PMID: 23940356).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 1417,
                "therapyName": "Buparlisib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 240,
                    "pubMedId": 23940356,
                    "title": "Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23940356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 969,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mouse breast cancer model with mammary ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23940356).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 240,
                    "pubMedId": 23940356,
                    "title": "Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23940356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 970,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mouse breast cancer model with ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Heceptin (trastuzumab) and Perjeta (pertuzumab) (PMID: 23940356).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 240,
                    "pubMedId": 23940356,
                    "title": "Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23940356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 971,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Perjeta (pertuzumab) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, with improved efficacy over Buparlisib (BKM120) alone (PMID: 23940356).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 1418,
                "therapyName": "Buparlisib + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 240,
                    "pubMedId": 23940356,
                    "title": "Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23940356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 972,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Tykerb (lapatinib) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, but efficacy was not significantly improved over Buparlisib (BKM120) alone (PMID: 23940356).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 1419,
                "therapyName": "Buparlisib + Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 240,
                    "pubMedId": 23940356,
                    "title": "Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23940356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 998,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT128930 induced growth arrest and inhibited tumor growth in a xenograft model of a ERBB2 (HER2)-positive human breast cancer cell line harboring a PIK3CA mutation (PMID: 21191045).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 1445,
                "therapyName": "CCT128930",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 692,
                    "pubMedId": 21191045,
                    "title": "Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21191045"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1043,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Dovitinib (TKI258) promoted 6-month stable disease in Erbb2 (Her2)-positive breast cancer patients with FGFR1 amplification (PMID: 23658459).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 754,
                    "pubMedId": 23658459,
                    "title": "Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23658459"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1373,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cell lines with a PIK3CA activating mutation and/or ERBB2 (HER2)-over expression demonstrated increased sensitivity to inhibition of proliferation by Aliqopa (copanlisib) in culture, compared to ERBB2 (HER2)-negative and wild-type PIK3CA cell lines (PMID: 24170767).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 995,
                "therapyName": "Copanlisib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 245,
                    "pubMedId": 24170767,
                    "title": "BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24170767"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1374,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Aliqopa (copanlisib) promoted tumor regression in xenograft models of a human ERBB2 (HER2)-amplified breast cancer cell line harboring a PIK3CA activating mutation (PMID: 24170767).",
            "molecularProfile": {
                "id": 19124,
                "profileName": "ERBB2 amp PIK3CA mut"
            },
            "therapy": {
                "id": 995,
                "therapyName": "Copanlisib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 245,
                    "pubMedId": 24170767,
                    "title": "BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24170767"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1748,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Dovitinib (TKI258) displayed safety and preliminary efficacy resulting in tumor regression of 28.2% and 18.5% in two patients with FGFR2 amplified Erbb2 (Her2)-receptor positive breast cancer (PMID: 23658459).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 754,
                    "pubMedId": 23658459,
                    "title": "Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23658459"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7743,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Kadclya (trastuzumab emtansine) demonstrated improved median progression free survival and overall survival compared to Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment in patients with ERBB2 (HER2) positive breast cancer, regardless of the expression level of Erbb2 (Her2), Egfr, and Her3, or PIK3CA mutation status (PMID: 26920887).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6466,
                    "pubMedId": 26920887,
                    "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26920887"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2021,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1503,
                "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2647,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NAX014 induced cellular senescence, prevented tumor growth, and decreased tumor volume in a Her2 positive breast cancer mouse model (PMID: 26168818).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 2984,
                "therapyName": "NAX014",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3369,
                    "pubMedId": 26168818,
                    "title": "Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26168818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2655,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, ERBB2 (HER2)-positive breast cancer patients treated with Gilotrif (afatinib), in combination with Herceptin (trastuzumab), demonstrated an overall objective response rate of 11% (2/18) while 28% (5/18) attained a best response of stable disease (PMID: 25370464).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1106,
                "therapyName": "Afatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3373,
                    "pubMedId": 25370464,
                    "title": "Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370464"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2737,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PKI-179 inhibited growth of breast cancer cells harboring PIK3CA mutations and ERBB2 (HER2) over expression in culture and cell line xenograft models (PMID: 20797855).",
            "molecularProfile": {
                "id": 26179,
                "profileName": "ERBB2 over exp PIK3CA mut"
            },
            "therapy": {
                "id": 872,
                "therapyName": "PKI-179",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1040,
                    "pubMedId": 20797855,
                    "title": "PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20797855"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2832,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, a breast cancer patient with ERBB2 (HER2) over expression that had progressed on Herceptin (trastuzumab) demonstrated stable disease for more than 12 weeks following treatment with CUDC-101 (PMID: 25107918).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1005,
                "therapyName": "CUDC-101",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3496,
                    "pubMedId": 25107918,
                    "title": "Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25107918"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2904,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I expansion trial, 36% (5/14) of metastatic breast cancer patients positive for ERBB2 (HER2) demonstrated stable disease for up to 16 weeks when treated with Varlitinib (ARRY-334543) (Cancer Res May 1, 2009 69; 3603).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1057,
                "therapyName": "Varlitinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3518,
                    "pubMedId": null,
                    "title": "Abstract #3603: ARRY-334543 in ErbB2 positive metastatic breast cancer and other ErbB expressing-cancers: experience from expansion cohorts on a phase I study",
                    "url": "http://cancerres.aacrjournals.org/content/69/9_Supplement/3603"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2915,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Tucatinib (ARRY-380) resulted in a response rate of 14% (3/22; all partial responses (PR)) and a clinical benefit rate (PR plus stable disease for greater than or equal to 24 weeks) of 27% (6/22) in Erbb2 (Her2)-positive breast cancer patients (PMID: 28053022).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 639,
                "therapyName": "Tucatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7781,
                    "pubMedId": 28053022,
                    "title": "Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28053022"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2924,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase I clinical trial, Margetuximab (MGAH22) displayed safety and had initial efficacy in patients with ERBB2 (HER2) positive breast cancer (J Clin Oncol 31, 2013 (suppl; abstr 3004)).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 808,
                "therapyName": "MGAH22",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 582,
                    "pubMedId": null,
                    "title": "Phase I study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody (MAb), in patients (pts) with advanced solid tumors expressing the HER2 oncoprotein.",
                    "url": "http://meetinglibrary.asco.org/content/115290-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2978,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Herceptin (trastuzumab) worked synergistically to inhibit growth of ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 19874578).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 3041,
                "therapyName": "Palbociclib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 805,
                    "pubMedId": 19874578,
                    "title": "PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19874578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2979,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tykerb (lapatinib) and Ibrance (palbociclib) worked additively to suppress growth of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 25221644).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 3042,
                "therapyName": "Lapatinib + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3547,
                    "pubMedId": 25221644,
                    "title": "CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25221644"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3124,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) inhibited PI3K signaling, cell growth and induced apoptosis in human breast cancer cells harboring ERBB2 (HER2) amplification, PIK3CA E545K, and PIK3CA K567R in culture and in cell line xenografts (PMID: 21325073, PMID: 17314276).",
            "molecularProfile": {
                "id": 11788,
                "profileName": "ERBB2 amp PIK3CA E545K PIK3CA K567R"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                },
                {
                    "id": 3636,
                    "pubMedId": 17314276,
                    "title": "Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17314276"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3205,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of ERBB2 (HER2)-positive breast cancer xenografts (PMID: 26005526).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2545,
                "therapyName": "BMS-906024",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3681,
                    "pubMedId": 26005526,
                    "title": "Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26005526"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3359,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Taxol (paclitaxel) plus Herceptin (trastuzumab) and Tykerb (lapatinib) resulted in a higher pathologic complete remission rate in ERBB2 (HER2)-receptor positive breast cancer patients with PIK3CA wild-type compared to those harboring a PIK3CA mutation (PMID: 26245675).",
            "molecularProfile": {
                "id": 430,
                "profileName": "PIK3CA wild-type"
            },
            "therapy": {
                "id": 3130,
                "therapyName": "Lapatinib + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3761,
                    "pubMedId": 26245675,
                    "title": "Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26245675"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7045,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib clinical trial, treatment with the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) resulted in an overall response rate of 47% (15/52) and median progression-free survival of 6.5 months in patients with ERBB2 (HER2)-positive metastatic breast cancer, including patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 513)).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1573,
                "therapyName": "Ado-trastuzumab emtansine + Tucatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6051,
                    "pubMedId": null,
                    "title": "Efficacy results of a phase 1b study of ont-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases.",
                    "url": "http://meetinglibrary.asco.org/content/170543-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3809,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) demonstrated clinical activity in CNS metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 12.5% (1/8) evaluable patients achieving CNS complete response, 25% (2/8) partial CNS response, and 62.5% (5/8) CNS stable disease (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1573,
                "therapyName": "Ado-trastuzumab emtansine + Tucatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4180,
                    "pubMedId": null,
                    "title": "[P4-14-19] ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)",
                    "url": "http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1267&terms="
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3806,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib clinical trial, treatment with the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) resulted in partial response in 33% (11/33) and stable disease in 48% (16/33) and a clinical benefit rate of 58% (19/33) in patients with ERBB2 (HER2)-positive metastatic breast cancer (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-20).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1573,
                "therapyName": "Ado-trastuzumab emtansine + Tucatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4179,
                    "pubMedId": null,
                    "title": "[P4-14-20] A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC)",
                    "url": "http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1338&terms="
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3807,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib clinical trial, the combination of Tucatinib (ARRY-380) and Herceptin (trastuzumab) demonstrated clinical activity in central nervous system (CNS) metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 100% (3/3) patients achieving CNS stable disease as best response (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1560,
                "therapyName": "Trastuzumab + Tucatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4180,
                    "pubMedId": null,
                    "title": "[P4-14-19] ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)",
                    "url": "http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1267&terms="
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3808,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination of Tucatinib (ARRY-380) with other agents demonstrated clinical activity in central nervous system (CNS) metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 1/1 evaluable patient treated with Tucatinib (ARRY-380) and Capecitabine achieving CNS partial response (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1577,
                "therapyName": "Capecitabine + Tucatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4180,
                    "pubMedId": null,
                    "title": "[P4-14-19] ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)",
                    "url": "http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1267&terms="
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3810,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination of Tucatinib (ARRY-380), Herceptin (trastuzumab), and Capecitabine demonstrated clinical activity in CNS metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 50% (1/2) of evaluable patients achieving CNS partial response and 50% (1/2) achieving CNS stable disease (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 3340,
                "therapyName": "Capecitabine + Trastuzumab + Tucatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4180,
                    "pubMedId": null,
                    "title": "[P4-14-19] ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)",
                    "url": "http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1267&terms="
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4370,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on Herceptin (trastuzumab)-based therapy (PMID: 24470511).",
            "molecularProfile": {
                "id": 23651,
                "profileName": "ERBB2 pos PTEN mut"
            },
            "therapy": {
                "id": 1417,
                "therapyName": "Buparlisib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 196,
                    "pubMedId": 24470511,
                    "title": "Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24470511"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4464,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Trodusquemine (MSI-1436) inhibited tumor growth and metastasis in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model (PMID: 24845231).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 3521,
                "therapyName": "Trodusquemine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4563,
                    "pubMedId": 24845231,
                    "title": "Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24845231"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4620,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-05280014 inhibited growth of ERBB2 (HER2)-over expressing breast cancer cells with activity comparable to Herceptin (trastuzumab) in culture (PMID: 25001079).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 3554,
                "therapyName": "PF-05280014",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4629,
                    "pubMedId": 25001079,
                    "title": "Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(\u00ae)).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25001079"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4784,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AT13148 inhibited tumor growth in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model harboring mutant PIK3CA (PMID: 22781553).",
            "molecularProfile": {
                "id": 25947,
                "profileName": "ERBB2 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3653,
                "therapyName": "AT13148",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 204,
                    "pubMedId": 22781553,
                    "title": "AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22781553"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5058,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RU-SKI 43 inhibited proliferation of ER-negative, ERBB2 amplified breast cancer cells positive for HHAT in culture (PMID: 25889650).",
            "molecularProfile": {
                "id": 20228,
                "profileName": "ERBB2 amp ESR1 neg HHAT pos"
            },
            "therapy": {
                "id": 3744,
                "therapyName": "RU-SKI 43",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4868,
                    "pubMedId": 25889650,
                    "title": "Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889650"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5059,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RU-SKI 43 worked synergistically with Tykerb (lapatinib) to inhibit proliferation of ERBB2 (HER2) amplified breast cancer cells positive for HHAT in culture (PMID: 25889650).",
            "molecularProfile": {
                "id": 20230,
                "profileName": "ERBB2 amp HHAT pos"
            },
            "therapy": {
                "id": 3745,
                "therapyName": "Lapatinib + RU-SKI 43",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4868,
                    "pubMedId": 25889650,
                    "title": "Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889650"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5079,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in complete response in the breast in 10.6% (7/66) and minimal residual disease in 16.7% (11/66) of ERBB2-positive breast cancer patients 11 days after receiving the treatment (European Breast Cancer Conference; Mar 2016; Abstract #6LBA).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4875,
                    "pubMedId": null,
                    "title": "Effects of perioperative lapatinib and trastuzumab, alone and in combination, in early HER2+ breast cancer - the UK EPHOS-B trial (CRUK/08/002)",
                    "url": "http://www.ecco-org.eu/Events/EBCC10/Abstract-search?abstractid=25368"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8433,
            "approvalStatus": "Clinical Study - Meta-analysis",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a meta-analysis of six randomized clinical trials, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in 13% absolute improvement in pathologic complete response rate in ERBB2 (HER2)-positive breast cancer patients compared to Herceptin (trastuzumab) single treatment (PMID: 27140927).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6655,
                    "pubMedId": 27140927,
                    "title": "Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27140927"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9165,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a retrospective analysis of the combined treatment, Herceptin (trastuzumab) and Tykerb (lapatinib), in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 28177460).",
            "molecularProfile": {
                "id": 25947,
                "profileName": "ERBB2 pos PIK3CA mut"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14695,
                    "pubMedId": 28177460,
                    "title": "Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28177460"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5246,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, ERBB2-positive breast cancer patients harboring PIK3CA mutations demonstrated lower pathologic complete remission rate (12.5%) compared to those with wild-type PIK3CA (48.4%) after Herceptin (trastuzumab) and Tykerb (lapatinib) combination therapy (PMID: 26245675).",
            "molecularProfile": {
                "id": 25947,
                "profileName": "ERBB2 pos PIK3CA mut"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3761,
                    "pubMedId": 26245675,
                    "title": "Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26245675"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5818,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, Kadcyla (trastuzumab emtansine) and Taxotere (docetaxel) combination treatment resulted in median progression-free survival of 13.8 months and objective response in 80.0% (20/25) of patients with ERBB2 (HER2)-positive metastatic breast cancer (PMID: 27052654).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 3930,
                "therapyName": "Ado-trastuzumab emtansine + Docetaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5158,
                    "pubMedId": 27052654,
                    "title": "Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27052654"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5819,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, Kadcyla (trastuzumab emtansine), Taxotere (docetaxel) and Perjeta (pertuzumab) combination treatment resulted in pathologic complete response in 60.3% (44/73) of patients with ERBB2 (HER2)-positive locally advanced breast cancer (PMID: 27052654).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 3931,
                "therapyName": "Ado-trastuzumab emtansine + Docetaxel + Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5158,
                    "pubMedId": 27052654,
                    "title": "Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27052654"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5857,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit survival of ERBB2 (HER2)-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 1409,
                "profileName": "ERBB2 pos PIK3CA act mut"
            },
            "therapy": {
                "id": 3956,
                "therapyName": "Palbociclib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5862,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in ERBB2 (HER2)-positive breast cancer cell lines harboring PTEN loss in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 1410,
                "profileName": "ERBB2 pos PTEN loss"
            },
            "therapy": {
                "id": 3956,
                "therapyName": "Palbociclib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6029,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tykerb (lapatinib) and MK2206 combination treatment resulted in stable disease for more than 6 months in 40% (2/5) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 27026198).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 4007,
                "therapyName": "Lapatinib + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5238,
                    "pubMedId": 27026198,
                    "title": "Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27026198"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6441,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-positive breast cancer (PMID: 26880266).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 2054,
                "therapyName": "CDX-3379",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5601,
                    "pubMedId": 26880266,
                    "title": "A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6442,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-amplified breast cancer (PMID: 26880266).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 2054,
                "therapyName": "CDX-3379",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5601,
                    "pubMedId": 26880266,
                    "title": "A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6443,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Herceptin (trastuzumab) and CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-amplified breast cancer, with increased efficacy compared to KTN3379 alone (PMID: 26880266).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 2064,
                "therapyName": "CDX-3379 + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5601,
                    "pubMedId": 26880266,
                    "title": "A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6465,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of PTEN expression resulted in a decreased response to treatment with CDX-3379 (KTN3379) in ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 26880266).",
            "molecularProfile": {
                "id": 23519,
                "profileName": "ERBB2 amp PTEN dec exp"
            },
            "therapy": {
                "id": 2054,
                "therapyName": "CDX-3379",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5601,
                    "pubMedId": 26880266,
                    "title": "A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880266"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6663,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).",
            "molecularProfile": {
                "id": 23664,
                "profileName": "ERBB2 pos PTEN dec exp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 213,
                    "pubMedId": 17936563,
                    "title": "A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17936563"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6715,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Entinostat and Tykerb (lapatinib) combination treatment resulted in complete response in 7% (1/15) and stable disease in 27% (4/15) of ERBB2 (HER2) positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 609)).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 4255,
                "therapyName": "Entinostat + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5776,
                    "pubMedId": null,
                    "title": "Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_170293.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6716,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, combination treatment consisted of Entinostat, Tykerb (lapatinib) and Herceptin (trastuzumab) resulted in complete response in 9% (2/22), partial response in 14% (3/22), and stable disease in 27% (6/22) of ERBB2 (HER2) positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 609)).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1542,
                "therapyName": "Entinostat + Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5776,
                    "pubMedId": null,
                    "title": "Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_170293.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6814,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, MYL-1401O demonstrated safety and efficacy comparable to Herceptin (trastuzumab) when given in combination with Taxol (paclitaxel), resulted in an objective response rate of 69.6% in ERBB2 (HER2)-positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr LBA503)).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 4263,
                "therapyName": "MYL-1401O + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5830,
                    "pubMedId": null,
                    "title": "Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin.",
                    "url": "http://meetinglibrary.asco.org/content/162159-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7148,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an ERBB2 (HER2) positive breast cancer cell line harboring CCNE1 amplification demonstrated sensitivity to treatment with Seliciclib in culture (AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 22).",
            "molecularProfile": {
                "id": 24499,
                "profileName": "CCNE1 amp ERBB2 pos"
            },
            "therapy": {
                "id": 1129,
                "therapyName": "Seliciclib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6108,
                    "pubMedId": null,
                    "title": "Abstract 22: Cyclin E amplification, a novel mechanism of resistance to trastuzumab in HER2 amplified breast cancer",
                    "url": "http://cancerres.aacrjournals.org/content/70/8_Supplement/22"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7744,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment resulted in decreased median progression free survival (4.3 vs. 6.4 months), median overall survival (17.3 vs. 27.8 months), and overall response rate(17.1% vs. 39.7%) in ERBB2 (HER2) positive breast cancer patients harboring PIK3CA mutations compared to PIK3CA wild type patients (PMID: 26920887).",
            "molecularProfile": {
                "id": 25947,
                "profileName": "ERBB2 pos PIK3CA mut"
            },
            "therapy": {
                "id": 1399,
                "therapyName": "Capecitabine + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6466,
                    "pubMedId": 26920887,
                    "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26920887"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7745,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",
            "molecularProfile": {
                "id": 25948,
                "profileName": "ERBB2 pos PIK3CA K111N"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6466,
                    "pubMedId": 26920887,
                    "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26920887"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7746,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture (PMID: 26920887).",
            "molecularProfile": {
                "id": 25949,
                "profileName": "ERBB2 pos PIK3CA I391M"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6466,
                    "pubMedId": 26920887,
                    "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26920887"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7747,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA C420R in culture (PMID: 26920887).",
            "molecularProfile": {
                "id": 25950,
                "profileName": "ERBB2 pos PIK3CA C420R"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6466,
                    "pubMedId": 26920887,
                    "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26920887"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7748,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA H1047R in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",
            "molecularProfile": {
                "id": 25951,
                "profileName": "ERBB2 pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6466,
                    "pubMedId": 26920887,
                    "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26920887"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7749,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA E545K in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",
            "molecularProfile": {
                "id": 20859,
                "profileName": "ERBB2 pos PIK3CA E545K"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6466,
                    "pubMedId": 26920887,
                    "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26920887"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7808,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Hertuzumab-vc-MMAE decreased viability of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 27509865).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 4583,
                "therapyName": "Hertuzumab-vc-MMAE",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6501,
                    "pubMedId": 27509865,
                    "title": "HER2-targeted antibody drug conjugates for ovarian cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27509865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7848,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-285 inhibited growth of breast cancer cell line harboring ERBB2 (HER2) over expression in culture and in cell line xenograft models (PMID: 23983820).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 2135,
                "therapyName": "TAK-285",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1960,
                    "pubMedId": 23983820,
                    "title": "Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23983820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8064,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-283 inhibited proliferation of ERBB2 (HER2) amplified breast cancer cells in culture (PMID: 26208524).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8169,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ADXS31-164 prevented development of spontaneous mammary tumors in Erbb2 (Her2)-over expressing transgenic animal models (PMID: 20725099).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 4654,
                "therapyName": "ADXS31-164",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6565,
                    "pubMedId": 20725099,
                    "title": "Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20725099"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8229,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Imbruvica (ibrutinib) inhibited Her family receptor signaling, resulted in apoptosis and growth inhibition in ERBB2 (HER2)-positive breast cancer cell lines in culture and in cell line xenograft models (PMID: 27256378).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6582,
                    "pubMedId": 27256378,
                    "title": "Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27256378"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8443,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Herceptin (trastuzumab) resulted in a decreased response in ERBB2 (HER2) receptor positive breast cancer cells with induced overexpression of CCND1 in culture (PMID: 26977878).",
            "molecularProfile": {
                "id": 1571,
                "profileName": "CCND1 over exp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6660,
                    "pubMedId": 26977878,
                    "title": "Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977878"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8444,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Tykerb (lapatinib) resulted in a decreased response in ERBB2 (HER2) receptor positive breast cancer cells with induced overexpression of CCND1 in culture (PMID: 26977878).",
            "molecularProfile": {
                "id": 1571,
                "profileName": "CCND1 over exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6660,
                    "pubMedId": 26977878,
                    "title": "Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977878"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8446,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Abemaciclib (LY2835219) to Tykerb (lapatinib) treatment enhanced growth inhibitory effects of Tykerb (lapatinib)-resistant ERBB2 (HER2)-receptor positive breast cancer cells in culture (PMID: 26977878).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4731,
                "therapyName": "Abemaciclib + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6660,
                    "pubMedId": 26977878,
                    "title": "Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977878"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8447,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an ERBB2 (HER2)-receptor positive breast cancer cell line xenograft model treated with Abemaciclib (LY2835219) demonstrated delayed tumor growth and in culture, resulted in some decreased cell viability (PMID: 26977878).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6660,
                    "pubMedId": 26977878,
                    "title": "Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977878"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8448,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Herceptin (trastuzumab) and Abemaciclib (LY2835219) resulted in tumor growth regresssion in an ERBB2 (HER2)-receptor positive breast cancer treatment refractory patient derived xenograft model and in ERBB2 (HER2)-receptor positive cultured cells, resulted in decreased cell viability (PMID: 26977878).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2259,
                "therapyName": "Abemaciclib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6660,
                    "pubMedId": 26977878,
                    "title": "Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977878"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8531,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-over expressing breast carcinoma cell lines in culture (PMID: 27450453).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6681,
                    "pubMedId": 27450453,
                    "title": "JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2-Targeted Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27450453"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19619,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (DESTINY-Breast01) that supported FDA approval, Enhertu (fam-trastuzumab deruxtecan-nxki) treatment resulted in an objective response rate of 60.9% (112/184) in patients with unresectable or metastatic ERBB2 (HER2)-positive breast cancer who have received two or more prior anti-HER2 therapies, with a median response duration of 14.8 months and a median progression-free survival of 16.4 months (PMID: 31825192; NCT03248492).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 4844,
                "therapyName": "Fam-trastuzumab deruxtecan-nxki",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17240,
                    "pubMedId": 31825192,
                    "title": "Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31825192"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8871,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Enhertu (fam-trastuzumab deruxtecan-nxki) inhibited growth of ERBB2 (HER2)-positive breast cancer cell lines in culture and xenograft models, and demonstrated antitumor activity in patient-derived xenograft (PDX) models of ERBB2 (HER2)-positive breast cancer, including models with low ERBB2 (HER2) expression (PMID: 27026201).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 4844,
                "therapyName": "Fam-trastuzumab deruxtecan-nxki",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6780,
                    "pubMedId": 27026201,
                    "title": "DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27026201"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8966,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cell line xenograft models harboring amplification of ERBB2 (HER2) and a PIK3CA mutation demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624).",
            "molecularProfile": {
                "id": 19124,
                "profileName": "ERBB2 amp PIK3CA mut"
            },
            "therapy": {
                "id": 747,
                "therapyName": "Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 191,
                    "pubMedId": 24141624,
                    "title": "Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24141624"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9163,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a retrospective analysis of Tykerb (lapatinib) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 28177460).",
            "molecularProfile": {
                "id": 25947,
                "profileName": "ERBB2 pos PIK3CA mut"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14695,
                    "pubMedId": 28177460,
                    "title": "Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28177460"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9164,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a retrospective analysis of Herceptin (trastuzumab) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 28177460).",
            "molecularProfile": {
                "id": 25947,
                "profileName": "ERBB2 pos PIK3CA mut"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14695,
                    "pubMedId": 28177460,
                    "title": "Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28177460"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9298,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to Herceptin (trastuzumab) in culture (PMID: 27172896).",
            "molecularProfile": {
                "id": 8724,
                "profileName": "ARID1A loss"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7065,
                    "pubMedId": 27172896,
                    "title": "Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27172896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9300,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to AZD8055 in culture (PMID: 27172896).",
            "molecularProfile": {
                "id": 8724,
                "profileName": "ARID1A loss"
            },
            "therapy": {
                "id": 1519,
                "therapyName": "AZD8055",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7065,
                    "pubMedId": 27172896,
                    "title": "Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27172896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9303,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial, ERBB2 (HER2) positive breast cancer patients with over expression of ANXA1 demonstrated a decreased survival benefit to Herceptin (trastuzumab) compared to treated ERBB2 (HER2) positive breast cancer patients with decreased expression of ANXA1 (PMID: 27172896).",
            "molecularProfile": {
                "id": 26814,
                "profileName": "ANXA1 over exp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7065,
                    "pubMedId": 27172896,
                    "title": "Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27172896"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9585,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Nerlynx (neratinib) plus Taxol (paclitaxel) demonstrated similar efficacy to Herceptin (trastuzumab) plus Taxol (paclitaxel), with an median progression-free survival of 12.9 months, however, potentially decreased CNS metastasis risk, with an incidence of 8.3% (20/242) compared to 17.3% (41/237) in the Herceptin (trastuzumab) plus Taxol (paclitaxel) group (PMID: 27078022).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 5101,
                "therapyName": "Neratinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7298,
                    "pubMedId": 27078022,
                    "title": "Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27078022"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9682,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CP-724,714 and XMU-MP-2 demonstrated synergy in inhibiting growth of a breast cancer cell line over expressing ERBB2 (HER2) and PTK6 in culture (PMID: 27758886).",
            "molecularProfile": {
                "id": 26972,
                "profileName": "ERBB2 over exp PTK6 over exp"
            },
            "therapy": {
                "id": 5157,
                "therapyName": "CP-724,714 + XMU-MP-2",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7466,
                    "pubMedId": 27758886,
                    "title": "Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758886"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9851,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Pyrotinib treatment resulted in an objective response rate of 50% (18/36, all partial responses), and a clinical benefit rate of 61.1% (22/36), and a median progression-free survival of 35.4 weeks in patients with ERBB2 (HER2)-positive breast cancer (PMID: 28498781, NCT01937689).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 3082,
                "therapyName": "Pyrotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7689,
                    "pubMedId": null,
                    "title": "Abstract P4-14-18: Phase I study of single-agent pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with ErbB2+ metastatic breast cancer",
                    "url": "http://cancerres.aacrjournals.org/content/76/4_Supplement/P4-14-18"
                },
                {
                    "id": 9800,
                    "pubMedId": 28498781,
                    "title": "Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28498781"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10673,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification and overexpression of Yes1 contributed to trastuzumab (Herceptin) resistance in Her2 positive breast cancer cells, in culture (PMID: 28158234).",
            "molecularProfile": {
                "id": 27723,
                "profileName": "YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8734,
                    "pubMedId": 28158234,
                    "title": "Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28158234"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10674,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification and overexpression of Yes1 contributed to lapatinib (Tykerb) resistance in Her2 positive breast cancer cells, in culture (PMID: 28158234).",
            "molecularProfile": {
                "id": 27723,
                "profileName": "YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8734,
                    "pubMedId": 28158234,
                    "title": "Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28158234"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10675,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, dasatinib (Sprycel) treatment of Her2 positive breast cancer cells with YES1 amplification and overexpression restored sensitivity to trastuzumab (Herceptin) (PMID: 28158234).",
            "molecularProfile": {
                "id": 27723,
                "profileName": "YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 5575,
                "therapyName": "Dasatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8734,
                    "pubMedId": 28158234,
                    "title": "Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28158234"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10676,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, dasatinib (Sprycel) treatment of Her2 positive breast cancer cells with YES1 amplification and overexpression restored sensitivity to lapatinib (Tykerb) (PMID: 28158234).",
            "molecularProfile": {
                "id": 27723,
                "profileName": "YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 5576,
                "therapyName": "Dasatinib + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8734,
                    "pubMedId": 28158234,
                    "title": "Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28158234"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10949,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) and Faslodex (fulvestrant) combination treatment resulted in an overall response rate of 29.8% (14/47; 4 complete responses, 10 partial responses), a median progression-free survival of 5.4 months, and median duration of response of 9.2 months in patients with ESR1-positive, ERBB2 (HER2)-mutant metastatic breast cancer (PMID: 31806627; NCT01953926).",
            "molecularProfile": {
                "id": 27861,
                "profileName": "ERBB2 mut ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8951,
                    "pubMedId": null,
                    "title": "Neratinib + fulvestrant in ERBB2-mutant, HER2\u2013non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial",
                    "url": "http://cancerres.aacrjournals.org/content/77/4_Supplement/PD2-08.short"
                },
                {
                    "id": 17785,
                    "pubMedId": 31806627,
                    "title": "Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806627"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10950,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Nerlynx (neratinib) treatment resulted in complete response in 12.5% (3/24) and partial response in 20.8% (5/24) of ERBB2 (HER2) mutant but not amplified breast cancer patients (Cancer Res 2017;77(4 Suppl):Abstract nr PD2-08).",
            "molecularProfile": {
                "id": 1216,
                "profileName": "ERBB2 mutant"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8951,
                    "pubMedId": null,
                    "title": "Neratinib + fulvestrant in ERBB2-mutant, HER2\u2013non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial",
                    "url": "http://cancerres.aacrjournals.org/content/77/4_Supplement/PD2-08.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11061,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, ERBB2 (HER2) positive breast cancer patients with diabetes demonstrated a greater disease free survival and overall survival when treated with Glucophage (metformin) compared to ERBB2 (HER2) positive breast cancer patients with diabetes not treated with Glucophage (metformin) (PMID: 28375706).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9054,
                    "pubMedId": 28375706,
                    "title": "Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28375706"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11142,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, adjuvant Herceptin (trastuzumab), Perjeta (pertuzumab), plus chemotherapy resulted in improved invasive disease-free survival compared to Herceptin (trastuzumab) plus chemotherapy in patients with Erbb2 (Her2)-positive breast cancer (J Clin Oncol 35, 2017 (suppl; abstr LBA500)).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9114,
                    "pubMedId": null,
                    "title": "APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).",
                    "url": "http://meetinglibrary.asco.org/record/145538/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11165,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Nerlynx (neratinib) and Xeloda (capecitabine) combination therapy resulted in an overall 12-month survival rate of 63% (23/37) in patients with Erbb2 (Her2)-positive breast cancer brain metastases (J Clin Oncol 35, 2017 (suppl; abstr 1005)).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1543,
                "therapyName": "Capecitabine + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9129,
                    "pubMedId": null,
                    "title": "TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).",
                    "url": "http://abstracts.asco.org/199/AbstView_199_186113.html"
                },
                {
                    "id": 15540,
                    "pubMedId": null,
                    "title": "Nerlynx (neratinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208051"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11356,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, CT-P6 demonstrated equivalence to reference Herceptin (trastuzumab) in patients with ERBB2 (HER2)-positive breast cancer, with 46.8% (116/248) of patients treated with CT-P6 achieving pathologic complete response compared to 50.4% (129/256) with Herceptin (trastuzumab) treatment (PMID: 28592386).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 5954,
                "therapyName": "CT-P6",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9249,
                    "pubMedId": 28592386,
                    "title": "CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28592386"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11548,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK-2206 and KRIBB11 synergistically inhibited growth of ERBB2 (HER2)-amplified breast cancer cell lines in culture (PMID: 28598816).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 6057,
                "therapyName": "KRIBB11 + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9624,
                    "pubMedId": 28598816,
                    "title": "Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28598816"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11671,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification of FGF3, FGF4, and FGF19 was associated with acquired resistance to combination treatment with Herceptin (trastuzumab) and Tykerb (lapatinib) in an ERBB2 (HER2)-amplified breast cancer cell line xenograft model (PMID: 28381415).",
            "molecularProfile": {
                "id": 28184,
                "profileName": "ERBB2 amp FGF19 amp FGF3 amp FGF4 amp"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9699,
                    "pubMedId": 28381415,
                    "title": "HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28381415"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12051,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ZW25 treatment resulted in partial response in 28.6% (2/7) and stable disease in 28.6% (2/7) of patients with ERBB2 (HER2)-positive breast cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 6240,
                "therapyName": "ZW25",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9992,
                    "pubMedId": null,
                    "title": "Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12065,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in a median progression-free survival of 4.04 months, and a disease control rate of 75.49% (77/102; 20 partial responses) in heavily-treated Erbb2 (Her2)-positive breast cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 237O; NCT02418689).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9996,
                    "pubMedId": null,
                    "title": "A phase II trial of pan-HER inhibitor Poziotinib, in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed regimens: The results of NOV120101-203 trial",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12066,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, SB3 treatment demonstrated safety, immunogenicity, and survival result similar to Herceptin (trastuzumab), resulted in event-free-survival rates of 92.2% and 91.6%, respectively, in patients with Erbb2 (Her2)-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 153PD; NCT02149524).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 6242,
                "therapyName": "SB3",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9997,
                    "pubMedId": null,
                    "title": "One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12067,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (LILAC) trial, Kanjinti (Trastuzumab-anns) treatment demonstrated safety and efficacy similar to Herceptin (trastuzumab) in neoadjuvant and adjuvant settings, resulted in a complete response in 48% (172/358) of patients with Erbb2 (Her2)-positive breast cancer, compared to 41% (137/338) in Herceptin (trastuzumab)-treated patients (PMID: 29880292; NCT01901146).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 6243,
                "therapyName": "Trastuzumab-anns",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17934,
                    "pubMedId": 29880292,
                    "title": "Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880292"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12278,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HER2 BATs demonstrated enhanced toxicity comparing to unarmed T-cells against Erbb2 (Her2)-positive breast cancer cells in culture (PMID: 11359672).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 6420,
                "therapyName": "HER2 BATs",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10259,
                    "pubMedId": 11359672,
                    "title": "Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11359672"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12343,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S63845 decreased viability of an ERBB2 (HER2)-amplified breast cancer cell line and ERBB2 (HER2)-amplified patient-derived xenograft (PDX) tumor cells in culture (PMID: 28768804).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4858,
                "therapyName": "S63845",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10337,
                    "pubMedId": 28768804,
                    "title": "Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28768804"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12348,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S63845 and Herceptin (trastuzumab) demonstrated synergy in ERBB2 (HER2)-amplified breast cancer cells in culture and in ERBB2 (HER2)-amplified breast cancer patient-derived xenograft (PDX) models, resulting in enhanced tumor growth inhibition and overall survival compared to either agent alone (PMID: 28768804).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 6470,
                "therapyName": "S63845 + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10337,
                    "pubMedId": 28768804,
                    "title": "Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28768804"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12350,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tykerb (lapatinib) and S63845 demonstrated synergy in an ERBB2 (HER2)-amplified breast cancer cell line in culture, resulting in decreased cell viability (PMID: 28768804).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 4859,
                "therapyName": "Lapatinib + S63845",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10337,
                    "pubMedId": 28768804,
                    "title": "Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28768804"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16393,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cell lines with ERBB2 (HER2) amplification and expressing ERBB2 L755S demonstrated decreased inhibition of ERBB2 (HER2) signaling and proliferation compared to cells expressing wild-type ERBB2 (HER2) following treatment with Tykerb (lapatinib) (PMID: 30301790).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12351,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2) L755S was associated with reactivation of ERBB2 (HER2) signaling and acquired resistance to Tykerb (lapatinib) in ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification in culture and in xenograft models (PMID: 28487443).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10339,
                    "pubMedId": 28487443,
                    "title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28487443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12352,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Tykerb (lapatinib) in ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 28487443).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10339,
                    "pubMedId": 28487443,
                    "title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28487443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12355,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Tykerb (lapatinib) plus Herceptin (trastuzumab) combination therapy in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10339,
                    "pubMedId": 28487443,
                    "title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28487443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16394,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cell lines with ERBB2 (HER2) amplification and expressing ERBB2 L755S demonstrated decreased inhibition proliferation compared to cells expressing wild-type ERBB2 (HER2) following treatment with Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 30301790).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12357,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Perjeta (pertuzumab) plus Herceptin (trastuzumab) combination therapy in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10339,
                    "pubMedId": 28487443,
                    "title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28487443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12359,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of ERBB2 (HER2) L755S resulted in decreased sensitivity to treatment with Kadcyla (trastuzumab emtansine) in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10339,
                    "pubMedId": 28487443,
                    "title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28487443"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12360,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth of ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification and harboring ERBB2 L755S in culture, and inhibited tumor growth in xenograft models (PMID: 28487443).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10339,
                    "pubMedId": 28487443,
                    "title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28487443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12361,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited growth of ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification and harboring ERBB2 L755S in culture (PMID: 28487443).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10339,
                    "pubMedId": 28487443,
                    "title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28487443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16387,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Nerlynx (neratinib) treatment resulted in partial response in 2 of 6 and disease stabilization in 4 of 6 breast cancer patients with ERBB2 (HER2) amplification and an ERBB2 (HER2) mutation, including stable disease in a patient harboring ERBB2 (HER2) L755S, and breast cancer cell lines with ERBB2 (HER2) amplification and expressing ERBB2 (HER2) L755S demonstrated sensitivity to Nerlynx (neratinib) in culture (PMID: 30301790).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12594,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, combination of Afinitor (everolimus) and Faslodex (fulvestrant) resulted in significantly improved progression-free survival compared to Faslodex (fulvestrant) monotherapy (HR=0.64, p=0.02) in estrogen-receptor positive breast cancer patients (San Antonio Breast Cancer Symposium, Dec 6, 2017, GS2-07; NCT02216786).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10465,
                    "pubMedId": null,
                    "title": "A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer",
                    "url": "http://www.abstracts2view.com/sabcs/view.php?nu=SABCS17L_741"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12942,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Nolvadex (tamoxifen) is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6704,
                "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12955,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Arimidex (anastrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6706,
                "therapyName": "Anastrozole + Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12956,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Femara (letrozole) is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6707,
                "therapyName": "Cyclophosphamide + Doxorubicin + Letrozole + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12958,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Aromasin (exemestane), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6708,
                "therapyName": "Cyclophosphamide + Doxorubicin + Exemestane + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13036,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Nolvadex (tamoxifen), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6710,
                "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13037,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Femara (letrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6711,
                "therapyName": "Cyclophosphamide + Doxorubicin + Letrozole + Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13038,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Arimidex (anastrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6712,
                "therapyName": "Anastrozole + Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13039,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Aromasin (exemestane), is indicated in guidelines for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6713,
                "therapyName": "Cyclophosphamide + Doxorubicin + Exemestane + Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13040,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab), followed by Nolvadex (tamoxifen), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6714,
                "therapyName": "Carboplatin + Docetaxel + Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13041,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab), followed by Arimidex (anastrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6715,
                "therapyName": "Anastrozole + Carboplatin + Docetaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13042,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab), followed by Femara (letrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6716,
                "therapyName": "Carboplatin + Docetaxel + Letrozole + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13043,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab), followed by Aromasin (exemestane), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6717,
                "therapyName": "Carboplatin + Docetaxel + Exemestane + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13044,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab), followed by Nolvadex (tamoxifen), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6718,
                "therapyName": "Carboplatin + Docetaxel + Pertuzumab + Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13045,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab), followed by Femara (letrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6719,
                "therapyName": "Carboplatin + Docetaxel + Letrozole + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13046,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab), followed by Aromasin (exemestane), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6721,
                "therapyName": "Carboplatin + Docetaxel + Exemestane + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13047,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) therapy is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1485,
                "therapyName": "Carboplatin + Docetaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13048,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 6434,
                "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13049,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab) therapy, is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1879,
                "therapyName": "Carboplatin + Docetaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13050,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Perjeta (pertuzumab), Herceptin (trastuzumab), and Taxol (paclitaxel) therapy is included in the guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1549,
                "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13051,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Perjeta (pertuzumab), Herceptin (trastuzumab), and Taxol (paclitaxel) therapy is included in the guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2) receptor-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1549,
                "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13090,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) in ERBB2 (HER2)-receptor positive breast cancer cells resulted in decreased phosphorylation of Erbb3 (Her3) in culture and complete tumor regression in 100% (8/8) of the cell line xenograft models compared to incomplete regression when treated with either agent alone (PMID: 21385943).",
            "molecularProfile": {
                "id": 29003,
                "profileName": "ERBB2 pos ERBB3 pos"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10961,
                    "pubMedId": 21385943,
                    "title": "Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21385943"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13148,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MEDI4276 treatment resulted in complete response in 1 patient with breast cancer, partial response in 1 patient with breast cancer, and stable disease in 12 patients with Erbb2 (Her2)-positive breast or gastric cancer (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 470; NCT02576548).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 6763,
                "therapyName": "MEDI4276",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10992,
                    "pubMedId": null,
                    "title": "Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer",
                    "url": "https://academic.oup.com/annonc/article/29/suppl_3/mdy048.005/4917517"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16897,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (KATHERINE) that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) resulted in improved invasive disease-free survival (HR=0.50, p<0.001) compared to Herceptin (trastuzumab) in patients with ERBB2 (HER2)-positive early breast cancer who had residual invasive disease after taxane and trastuzumab-based neoadjuvant therapy (PMID: 30516102; NCT01772472).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15036,
                    "pubMedId": 30516102,
                    "title": "Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30516102"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15510,
                    "pubMedId": null,
                    "title": "Kadclya (trastuzumab emtansine) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20052,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Kadcyla (ado-trastuzumab emtansine) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17466,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Kadcyla (ado-trastuzumab emtansine) is included in the guidelines for patients with ERBB2 (HER2)-positive advanced breast cancer who progressed through one line of Herceptin (trastuzumab)-based therapy or ERBB2 (HER2)-positive patients with early breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15502,
                    "pubMedId": 31236598,
                    "title": "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236598"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13882,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (EMILIA) that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) improved median progression free survival (9.6 mo vs 6.4 mo) and overall survival (30.9 mo vs 25.1 mo) compared to Tykerb (lapatinib) combined with Xeloda (capecitabine) in patients with metastatic ERBB2 (HER2)-positive breast cancer (PMID: 24879797, PMID: 23020162; NCT00829166).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2499,
                    "pubMedId": 24879797,
                    "title": "FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24879797"
                },
                {
                    "id": 10786,
                    "pubMedId": 23020162,
                    "title": "Trastuzumab emtansine for HER2-positive advanced breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23020162"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15510,
                    "pubMedId": null,
                    "title": "Kadclya (trastuzumab emtansine) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16898,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (KATHERINE) that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) resulted in improved invasive disease-free survival (HR=0.50, p<0.001) compared to Herceptin (trastuzumab) in patients with ERBB2 (HER2)-positive early breast cancer who had residual invasive disease after taxane and trastuzumab-based neoadjuvant therapy (PMID: 30516102; NCT01772472).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15036,
                    "pubMedId": 30516102,
                    "title": "Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30516102"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15510,
                    "pubMedId": null,
                    "title": "Kadclya (trastuzumab emtansine) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20051,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Kadcyla (ado-trastuzumab emtansine) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13883,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (EMILIA) that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) improved median progression free survival (9.6 mo vs 6.4 mo) and overall survival (30.9 mo vs 25.1 mo) compared to Tykerb (lapatinib) combined with Xeloda (capecitabine) in patients with metastatic ERBB2 (HER2)-positive breast cancer (PMID: 24879797, PMID: 23020162; NCT00829166).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2499,
                    "pubMedId": 24879797,
                    "title": "FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24879797"
                },
                {
                    "id": 10786,
                    "pubMedId": 23020162,
                    "title": "Trastuzumab emtansine for HER2-positive advanced breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23020162"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15510,
                    "pubMedId": null,
                    "title": "Kadclya (trastuzumab emtansine) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17467,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Kadcyla (ado-trastuzumab emtansine) is included in the guidelines for ERBB2 (HER2)-positive patients with advanced breast cancer who progressed through one line of Herceptin (trastuzumab)-based therapy or ERBB2 (HER2)-positive patients with early breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15502,
                    "pubMedId": 31236598,
                    "title": "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236598"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14956,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with increased expression of NT5E (CD73) had no significant benefit to Herceptin (trastuzumab) (PMID: 28855210).",
            "molecularProfile": {
                "id": 30398,
                "profileName": "ERBB2 amp NT5E over exp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11853,
                    "pubMedId": 28855210,
                    "title": "CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28855210"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14957,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with increased expression of Pdcd1 (PD-1) had significant benefit to Herceptin (trastuzumab) (PMID: 28855210).",
            "molecularProfile": {
                "id": 30400,
                "profileName": "ERBB2 amp PDCD1 over exp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11853,
                    "pubMedId": 28855210,
                    "title": "CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28855210"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14958,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with increased expression of Cd274 (PD-l1) had significant benefit to Herceptin (trastuzumab) (PMID: 28855210).",
            "molecularProfile": {
                "id": 30401,
                "profileName": "CD274 over exp ERBB2 amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11853,
                    "pubMedId": 28855210,
                    "title": "CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28855210"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16199,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (HannaH) that supported FDA approval, Herceptin Hylecta (trastuzumab and hyaluronidase-oysk injection) treatment demonstrated safety and efficacy profile comparable to intravenous trastuzumab treatment, resulted in pathologic complete response in 45.4% (118/260) of patients with ERBB2 (HER2)-positive (IHC 3+ or ISH positive) breast cancer (PMID: 22884505; NCT00950300).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 7914,
                "therapyName": "trastuzumab and hyaluronidase-oysk injection",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14318,
                    "pubMedId": 22884505,
                    "title": "Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22884505"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15538,
                    "pubMedId": null,
                    "title": "Herceptin Hylecta (trastuzumab and hyaluronidase-oysk injection) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761106"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16200,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (HannaH) that supported FDA approval, Herceptin Hylecta (trastuzumab and hyaluronidase-oysk injection) treatment demonstrated safety and efficacy profile comparable to intravenous trastuzumab treatment, resulted in pathologic complete response in 45.4% (118/260) of patients with ERBB2 (HER2)-positive (IHC 3+ or ISH positive) breast cancer (PMID: 22884505; NCT00950300).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 7914,
                "therapyName": "trastuzumab and hyaluronidase-oysk injection",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14318,
                    "pubMedId": 22884505,
                    "title": "Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22884505"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15538,
                    "pubMedId": null,
                    "title": "Herceptin Hylecta (trastuzumab and hyaluronidase-oysk injection) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761106"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16388,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Nerlynx (neratinib) treatment resulted in partial response in 2 of 6 and disease stabilization in 4 of 6 breast cancer patients with ERBB2 (HER2) amplification and an ERBB2 (HER2) mutation, including stable disease in a patient harboring ERBB2 (HER2) Y772_A775dup (PMID: 30301790).",
            "molecularProfile": {
                "id": 31621,
                "profileName": "ERBB2 Y772_A775dup ERBB2 amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16389,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Nerlynx (neratinib) treatment resulted in partial response in 2 of 6 and disease stabilization in 4 of 6 breast cancer patients with ERBB2 (HER2) amplification and an ERBB2 (HER2) mutation, including stable disease in a patient harboring ERBB2 (HER2) D769Y, and Nerlynx (neratinib) inhibited tumor growth in a breast cancer patient-derived xenograft (PDX) model with ERBB2 (HER2) amplification and ERBB2 (HER2) D769Y (PMID: 30301790).",
            "molecularProfile": {
                "id": 31622,
                "profileName": "ERBB2 D769Y ERBB2 amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16390,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Nerlynx (neratinib) treatment resulted in partial response in 2 of 6 and disease stabilization in 4 of 6 breast cancer patients with ERBB2 (HER2) amplification and an ERBB2 (HER2) mutation, including partial response in a patient harboring ERBB2 (HER2) V777L (PMID: 30301790).",
            "molecularProfile": {
                "id": 31623,
                "profileName": "ERBB2 V777L ERBB2 amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16391,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer patient-derived xenograft (PDX) model with ERBB2 (HER2) amplification and ERBB2 D769Y was refractory to treatment with Herceptin (trastuzumab) (PMID: 30301790).",
            "molecularProfile": {
                "id": 31622,
                "profileName": "ERBB2 D769Y ERBB2 amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16392,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer patient-derived xenograft (PDX) model with ERBB2 (HER2) amplification and ERBB2 D769Y was refractory to treatment with Tykerb (lapatinib) (PMID: 30301790).",
            "molecularProfile": {
                "id": 31622,
                "profileName": "ERBB2 D769Y ERBB2 amp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16395,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cell lines with ERBB2 (HER2) amplification and expressing ERBB2 L755S demonstrated decreased inhibition proliferation compared to cells expressing wild-type ERBB2 (HER2) following treatment with Herceptin (trastuzumab) (PMID: 30301790).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16396,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Nerlynx (neratinib) treatment resulted in partial response in 2 of 6 and disease stabilization in 4 of 6 breast cancer patients with ERBB2 (HER2) amplification and an ERBB2 (HER2) mutation, including stable disease in a patient harboring ERBB2 (HER2) R456C (PMID: 30301790).",
            "molecularProfile": {
                "id": 31627,
                "profileName": "ERBB2 R456C ERBB2 amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16397,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Nerlynx (neratinib) treatment resulted in partial response in 2 of 6 and disease stabilization in 4 of 6 breast cancer patients with ERBB2 (HER2) amplification and an ERBB2 (HER2) mutation, including partial response in a patient harboring ERBB2 (HER2) L313I (PMID: 30301790).",
            "molecularProfile": {
                "id": 31626,
                "profileName": "ERBB2 L313I ERBB2 amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16769,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GBR 1302 treatment resulted in prolonged (more than 4 months) stable disease in a patient with ERBB2 (HER2) positive (IHC 2+) breast adenocarcinoma (Annals of Oncology, Volume 29, Issue suppl_8, October 2018, mdy288.020; NCT02829372).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 8171,
                "therapyName": "GBR1302",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14826,
                    "pubMedId": null,
                    "title": "GBR1302: a BEAT bispecific antibody for the treatment of HER2 positive cancers",
                    "url": "https://www.ejcancer.com/article/S0959-8049(14)70265-5/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16771,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS0728 inhibited Erbb2 downstream signaling and proliferation of ERBB2 (HER2) amplified breast cancer cell lines in culture, and induced tumor regression in cell line xenograft models (PMID: 30787176).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 8170,
                "therapyName": "TAS0728",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14833,
                    "pubMedId": 30787176,
                    "title": "TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30787176"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17057,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab), followed by Arimidex (anastrozole), is iincluded in the guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6720,
                "therapyName": "Anastrozole + Carboplatin + Docetaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17070,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Arimidex (anastrozole) and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8401,
                "therapyName": "Anastrozole + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17072,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Femara (letrozole) and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8403,
                "therapyName": "Letrozole + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17073,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Aromasin (exemestane) and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8404,
                "therapyName": "Exemestane + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17074,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Arimidex (anastrozole) and Tykerb (lapatinib) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8405,
                "therapyName": "Anastrozole + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17075,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Femara (letrozole) and Tykerb (lapatinib) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 1497,
                "therapyName": "Lapatinib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17078,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Aromasin (exemestane) and Tykerb (lapatinib) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8406,
                "therapyName": "Exemestane + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17079,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Arimidex (anastrozole), Tykerb (lapatinib), and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8407,
                "therapyName": "Anastrozole + Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17083,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Femara (letrozole), Tykerb (lapatinib), and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8408,
                "therapyName": "Lapatinib + Letrozole + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17084,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Aromasin (exemestane), Tykerb (lapatinib), and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8409,
                "therapyName": "Exemestane + Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17086,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Faslodex (fulvestrant) and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8410,
                "therapyName": "Fulvestrant + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17092,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Nolvadex (tamoxifen) and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8411,
                "therapyName": "Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17482,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) is FDA approved as an adjuvant treatment for ERBB2 (HER2)-overexpressing (or amplification) breast cancer patients and for metastatic ERBB2 (HER2)-overexpressing (or amplification) breast cancer patients as indicated by an FDA approved companion diagnostic (FDA.gov).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15509,
                    "pubMedId": null,
                    "title": "Herceptin (trastuzumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103792"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17455,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) combined with a taxane, such as Taxotere (docetaxel) or Taxol (paclitaxel), is included in guidelines as neoadjuvant therapy for patients with ERBB2 (HER2)-positive early breast cancer or as first-line therapy for patients with ERBB2 (HER2)-positive advanced breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15502,
                    "pubMedId": 31236598,
                    "title": "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236598"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17458,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Herceptin (trastuzumab) and Perjeta (pertuzumab) with a taxane, such as Taxotere (docetaxel) or Taxol (palictaxel), is included in guidelines for patients with ERBB2 (HER2)-positive early breast cancer patients or advanced breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15502,
                    "pubMedId": 31236598,
                    "title": "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236598"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17459,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Herceptin (trastuzumab) and Perjeta (pertuzumab) with a taxane, such as Taxotere (docetaxel) or Taxol (palictaxel), is included in guidelines for ERBB2 (HER2)-positive patients with early breast cancer patients or advanced breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15502,
                    "pubMedId": 31236598,
                    "title": "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236598"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20056,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) combined with Navelbine (vinorelbine) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1890,
                "therapyName": "Trastuzumab + Vinorelbine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17461,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Herceptin (trastuzumab) and Navelbine (vinorelbine) is included in guidelines as first-line therapy for patients with ERBB2 (HER2)-positive advanced breast cancer (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1890,
                "therapyName": "Trastuzumab + Vinorelbine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20055,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) combined with Navelbine (vinorelbine) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1890,
                "therapyName": "Trastuzumab + Vinorelbine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17462,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Herceptin (trastuzumab) and Navelbine (vinorelbine) is included in guidelines as first-line therapy for ERBB2 (HER2)-positive patients with advanced breast cancer (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1890,
                "therapyName": "Trastuzumab + Vinorelbine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17464,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Herceptin (trastuzumab) and Tykerb (lapatinib) is included in guidelines for patients with ERBB2 (HER2)-positive advanced breast cancer who progressed on Herceptin (trastuzumab)-based therapy, however, the combination therapy is not recommended as neoadjuvant therapy for ERBB2 (HER2)-positive patients with early breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15502,
                    "pubMedId": 31236598,
                    "title": "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236598"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20061,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) combined with Tykerb (lapatinib) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17515,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, ERBB2 (HER2)-positive (overexpressing and/or amplification) breast cancer patients previously treated with Herceptin (trastuzumab) demonstrated a significantly greater two year invasive disease-free survival rate (93.9%) when treated with Nerlynx (neratinib) compared to the rate (91.6%) in those patients treated with placebo (PMID: 26874901; NCT00878709).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9591,
                    "pubMedId": 26874901,
                    "title": "Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26874901"
                },
                {
                    "id": 15540,
                    "pubMedId": null,
                    "title": "Nerlynx (neratinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208051"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17469,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Nerlynx (neratinib) is included in guidelines for ERBB2 (HER2)-positive patients with high-risk early breast cancer (PMID: 31236598; ESMO.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15502,
                    "pubMedId": 31236598,
                    "title": "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236598"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17514,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, ERBB2 (HER2)-positive (overexpressing and/or amplification) breast cancer patients previously treated with Herceptin (trastuzumab) demonstrated a significantly greater two year invasive disease-free survival rate (93.9%) when treated with Nerlynx (neratinib) compared to the rate (91.6%) in those patients treated with placebo (PMID: 26874901; NCT00878709).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9591,
                    "pubMedId": 26874901,
                    "title": "Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26874901"
                },
                {
                    "id": 15540,
                    "pubMedId": null,
                    "title": "Nerlynx (neratinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208051"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17470,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Nerlynx (neratinib) is included in guidelines for patients with high-risk ERBB2 (HER2)-positive early breast cancer (PMID: 31236598; ESMO.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15502,
                    "pubMedId": 31236598,
                    "title": "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236598"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20065,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Perjeta (pertuzumab), Herceptin (trastuzumab), and Taxotere (docetaxel) therapy is included in the guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1978,
                "therapyName": "Docetaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17483,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CLEOPATRA) that supported FDA approval, treatment with Perjeta (pertuzumab), combined with Herceptin (trastuzumab) and Taxotere (docetaxel), improved median progression free survival to 18.5 months compared to 12.4 months with placebo plus Herceptin (trastuzumab) and Taxotere (docetaxel) in patients with ERBB2 (HER2)-positive (overexpression and amplification) metastatic breast cancer (PMID: 23801166).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1978,
                "therapyName": "Docetaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 564,
                    "pubMedId": 23801166,
                    "title": "First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23801166"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15511,
                    "pubMedId": null,
                    "title": "Perjeta (pertuzumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20064,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Perjeta (pertuzumab), Herceptin (trastuzumab), and Taxotere (docetaxel) therapy is included in the guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1978,
                "therapyName": "Docetaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17484,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CLEOPATRA) that supported FDA approval, treatment with Perjeta (pertuzumab), combined with Herceptin (trastuzumab) and Taxotere (docetaxel), improved median progression free survival to 18.5 months compared to 12.4 months with placebo plus Herceptin (trastuzumab) and Taxotere (docetaxel) in patients with ERBB2 (HER2)-positive (overexpression and amplification) metastatic breast cancer (PMID: 23801166).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1978,
                "therapyName": "Docetaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 564,
                    "pubMedId": 23801166,
                    "title": "First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23801166"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15511,
                    "pubMedId": null,
                    "title": "Perjeta (pertuzumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17489,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Herceptin (trastuzumab) and Perjeta (pertuzumab) with chemotherapy or endocrine therapy is included in guidelines as first line therapy for advanced ERBB2 (HER2)-positive, ESR1-positive breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 28936,
                "profileName": "ERBB2 over exp ESR1 pos"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17490,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Herceptin (trastuzumab) and Perjeta (pertuzumab) with chemotherapy or endocrine therapy is included in guidelines as first line therapy for advanced ERBB2 (HER2)-positive, ESR1-positive breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 32622,
                "profileName": "ERBB2 amp ESR1 pos"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17491,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) combined with chemotherapy or endocrine therapy is included in guidelines as first line therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 32622,
                "profileName": "ERBB2 amp ESR1 pos"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17492,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) combined with chemotherapy or endocrine therapy is included in guidelines as first line therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 28936,
                "profileName": "ERBB2 over exp ESR1 pos"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17493,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tykerb (lapatinib) combined with endocrine therapy is included in guidelines as first-line therapy or maintenance therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 32622,
                "profileName": "ERBB2 amp ESR1 pos"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17494,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tykerb (lapatinib) combined with endocrine therapy is included in guidelines as first-line therapy or maintenance therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 28936,
                "profileName": "ERBB2 over exp ESR1 pos"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17495,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Tykerb (lapatinib) and Herceptin (trastuzumab) with endocrine therapy is included in guidelines as first line therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 32622,
                "profileName": "ERBB2 amp ESR1 pos"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17496,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Tykerb (lapatinib) and Herceptin (trastuzumab) with endocrine therapy is included in guidelines as first line therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 28936,
                "profileName": "ERBB2 over exp ESR1 pos"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17497,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Kadcyla (ado-trastuzumab emtansine) is included in guidelines as second line therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients who have progressed on first line therapy (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 32622,
                "profileName": "ERBB2 amp ESR1 pos"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17498,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Kadcyla (ado-trastuzumab emtansine) is included in guidelines as second line therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients who have progressed on first line therapy (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 28936,
                "profileName": "ERBB2 over exp ESR1 pos"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17745,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).",
            "molecularProfile": {
                "id": 25947,
                "profileName": "ERBB2 pos PIK3CA mut"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15759,
                    "pubMedId": 30867034,
                    "title": "PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867034"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17746,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).",
            "molecularProfile": {
                "id": 32788,
                "profileName": "ERBB2 pos PIK3CA amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15759,
                    "pubMedId": 30867034,
                    "title": "PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867034"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17747,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).",
            "molecularProfile": {
                "id": 25951,
                "profileName": "ERBB2 pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15759,
                    "pubMedId": 30867034,
                    "title": "PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867034"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17749,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).",
            "molecularProfile": {
                "id": 32789,
                "profileName": "ERBB2 pos PIK3CA E542K"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15759,
                    "pubMedId": 30867034,
                    "title": "PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867034"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17750,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).",
            "molecularProfile": {
                "id": 20859,
                "profileName": "ERBB2 pos PIK3CA E545K"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15759,
                    "pubMedId": 30867034,
                    "title": "PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867034"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17751,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).",
            "molecularProfile": {
                "id": 32790,
                "profileName": "ERBB2 pos PIK3CA E545D"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15759,
                    "pubMedId": 30867034,
                    "title": "PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867034"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18491,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Pyrotinib and Xeloda (capecitabine) combination treatment was well-tolerated, and resulted in an overall response rate of 78.6% (22/28) in patients with Erbb2 (Her2)-positive metastatic breast cancer, with a median progression-free survival of 22.1 months (PMID: 31138588; NCT02361112).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 8730,
                "therapyName": "Capecitabine + Pyrotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16274,
                    "pubMedId": 31138588,
                    "title": "Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31138588"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18715,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 33510,
                "profileName": "ERBB2 amp PIK3CA act mut"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18716,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 33511,
                "profileName": "ERBB2 over exp PIK3CA act mut"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18717,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 33516,
                "profileName": "ERBB2 amp PIK3CA E542X"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18718,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 33517,
                "profileName": "ERBB2 over exp PIK3CA E542X"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18719,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 33518,
                "profileName": "ERBB2 over exp PIK3CA E545X"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18720,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 33525,
                "profileName": "ERBB2 amp PIK3CA E545X"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18721,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 33521,
                "profileName": "ERBB2 amp PIK3CA H1047X"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18723,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 33522,
                "profileName": "ERBB2 over exp PIK3CA H1047X"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18726,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, increased copy number (CN) of ERBB2 (HER2) was associated with improved response to Poziotinib (HM781-36B) treatment in patients with Erbb2 (Her2)-positive breast cancer, with a median progression-free survival of 4.86 months in patients with CN over 8 and 2.99 months in patients with CN equal to or less than 8 (HR=0.61, p=0.037) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18727,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the presence of ERBB3 single nucleotide variants (SNVs) was associated with shorter progression-free survival (wild-type vs mutant, 3.75 vs 1.48 months, HR=1.59, p=0.176) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B), and SNVs in the cytoplasmic domain correlated with further decreased response (1.38 vs 4.07 months, HR=4.58, p<0.001) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 33526,
                "profileName": "ERBB2 amp ERBB3 mut"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18729,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the presence of ERBB3 single nucleotide variants (SNVs) was associated with shorter progression-free survival (wild-type vs mutant, 3.75 vs 1.48 months, HR=1.59, p=0.176) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B), and SNVs in the cytoplasmic domain correlated with further decreased response (1.38 vs 4.07 months, HR=4.58, p<0.001) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 33527,
                "profileName": "ERBB2 over exp ERBB3 mut"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18730,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the presence of high ERBB2 (HER2) copy number and wild-type PIK3CA correlated with improved progression-free survival (HR=0.45, p=0.024) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 26704,
                "profileName": "ERBB2 amp PIK3CA wild-type"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20049,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin combined with Paraplatin (carboplatin) and Taxol (paclitaxel) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1887,
                "therapyName": "Carboplatin + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20050,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin combined with Paraplatin (carboplatin) and Taxol (paclitaxel) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1887,
                "therapyName": "Carboplatin + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20053,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) combined with Taxotere (docetaxel) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 9275,
                "therapyName": "Docetaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20054,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) combined with Taxotere (docetaxel) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 9275,
                "therapyName": "Docetaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20057,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) combined with Xeloda (capecitabine) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1409,
                "therapyName": "Capecitabine + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20058,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) combined with Xeloda (capecitabine) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1409,
                "therapyName": "Capecitabine + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20059,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tykerb (lapatinib) combined with Xeloda (capecitabine) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1399,
                "therapyName": "Capecitabine + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20062,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) combined with Tykerb (lapatinib) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20063,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Nerlynx (neratinib) combined with Xeloda (capecitabine) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1543,
                "therapyName": "Capecitabine + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20604,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (NALA) trial that supported FDA approval, combination of Nerlynx (neratinib) and Xeloda (capecitabine) reduced risk of disease progression or death (HR=0.76, p=0.006), improved 12-month PFS (28.8%, 88/307 vs 14.8%, 46/314) compared to lapatinib and capecitabine combination in patients with metastatic ERBB2 (HER2)-positive (amp/over exp) breast cancer who had 2 or more prior ERBB2 (HER2)-targeted therapies (J Clin Oncol 37, no. 15_suppl (May 20, 2019) 1002-1002; NCT01808573).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1543,
                "therapyName": "Capecitabine + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15540,
                    "pubMedId": null,
                    "title": "Nerlynx (neratinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208051"
                },
                {
                    "id": 17957,
                    "pubMedId": null,
                    "title": "Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with >= 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.1002"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20569,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (LILAC) trial, Kanjinti (Trastuzumab-anns) treatment demonstrated safety and efficacy similar to Herceptin (trastuzumab) in neoadjuvant and adjuvant settings, resulted in a complete response in 48% (172/358) of patients with Erbb2 (Her2)-positive breast cancer, compared to 41% (137/338) in Herceptin (trastuzumab)-treated patients (PMID: 29880292; NCT01901146).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 6243,
                "therapyName": "Trastuzumab-anns",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17934,
                    "pubMedId": 29880292,
                    "title": "Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880292"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20602,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Enhertu (fam-trastuzumab deruxtecan-nxki) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 4844,
                "therapyName": "Fam-trastuzumab deruxtecan-nxki",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20603,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Enhertu (fam-trastuzumab deruxtecan-nxki) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 4844,
                "therapyName": "Fam-trastuzumab deruxtecan-nxki",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20605,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (NALA) trial that supported FDA approval, combination of Nerlynx (neratinib) and Xeloda (capecitabine) reduced risk of disease progression or death (HR=0.76, p=0.006), improved 12-month PFS (28.8%, 88/307 vs 14.8%, 46/314) compared to lapatinib and capecitabine combination in patients with metastatic ERBB2 (HER2)-positive (amp/over exp) breast cancer who had 2 or more prior ERBB2 (HER2)-targeted therapies (J Clin Oncol 37, no. 15_suppl (May 20, 2019) 1002-1002; NCT01808573).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1543,
                "therapyName": "Capecitabine + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17957,
                    "pubMedId": null,
                    "title": "Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with >= 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.1002"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20826,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MBS301 inhibited proliferation of ERBB2 (HER2)-positive breast cancer cell lines expressing high or low levels of ERBB2 (HER2) in culture, and inhibited tumor growth in xenograft models (PMID: 30081724).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 9493,
                "therapyName": "MBS301",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18091,
                    "pubMedId": 30081724,
                    "title": "Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30081724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21014,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, ERBB2 (HER2) G778_P780dup (reported as P780_Y781insGSP) was identified in a patient with ERBB2 (HER2)-positive breast cancer at the time of disease progression while on Tykerb (lapatinib) treatment (PMID: 31980423).",
            "molecularProfile": {
                "id": 3278,
                "profileName": "ERBB2 G778_P780dup"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18263,
                    "pubMedId": 31980423,
                    "title": "An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31980423"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00411788",
            "title": "A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1979,
                    "therapyName": "Sirolimus + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00574587",
            "title": "Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1983,
                    "therapyName": "Paclitaxel + Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01016886",
            "title": "Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1897,
                    "therapyName": "Bisoprolol",
                    "synonyms": null
                },
                {
                    "id": 1896,
                    "therapyName": "Perindopril",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01160211",
            "title": "A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1414,
                    "therapyName": "Lapatinib + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                },
                {
                    "id": 633,
                    "therapyName": "Anastrozole",
                    "synonyms": null
                },
                {
                    "id": 787,
                    "therapyName": "Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 738,
                    "therapyName": "Exemestane",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01177397",
            "title": "Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 693,
                    "therapyName": "CC-223",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01273610",
            "title": "Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1414,
                    "therapyName": "Lapatinib + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01276041",
            "title": "Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01300962",
            "title": "Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1538,
                    "therapyName": "Buparlisib + Capecitabine + Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 1537,
                    "therapyName": "Buparlisib + Capecitabine + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1536,
                    "therapyName": "Buparlisib + Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 1535,
                    "therapyName": "Alpelisib + Capecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01305941",
            "title": "A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1411,
                    "therapyName": "Everolimus + Trastuzumab + Vinorelbine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01325207",
            "title": "Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01434303",
            "title": "Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1542,
                    "therapyName": "Entinostat + Lapatinib + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01491737",
            "title": "A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (PERTAIN)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 633,
                    "therapyName": "Anastrozole",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01494662",
            "title": "HKI-272 for HER2-Positive Breast Cancer and Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1543,
                    "therapyName": "Capecitabine + Neratinib",
                    "synonyms": null
                },
                {
                    "id": 828,
                    "therapyName": "Neratinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01513083",
            "title": "A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01526473",
            "title": "A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1068,
                    "therapyName": "AVX901",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01565083",
            "title": "A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1666,
                    "therapyName": "Pertuzumab + Trastuzumab + Vinorelbine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01566721",
            "title": "A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01602406",
            "title": "Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2037,
                    "therapyName": "LJM716 + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01622868",
            "title": "Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 787,
                    "therapyName": "Lapatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01702558",
            "title": "A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                },
                {
                    "id": 1976,
                    "therapyName": "Ado-trastuzumab emtansine + Capecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01702571",
            "title": "A Study of Kadcyla (Trastuzumab Emtansine) in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01730118",
            "title": "Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1404,
                    "therapyName": "HER2 Vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01772472",
            "title": "A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01783756",
            "title": "Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1552,
                    "therapyName": "Capecitabine + Everolimus + Lapatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01796197",
            "title": "Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01808573",
            "title": "A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1399,
                    "therapyName": "Capecitabine + Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 1543,
                    "therapyName": "Capecitabine + Neratinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01816035",
            "title": "Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01828021",
            "title": "Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 808,
                    "therapyName": "MGAH22",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01848756",
            "title": "Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 866,
                    "therapyName": "SNX-5422",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01853748",
            "title": "T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1551,
                    "therapyName": "Paclitaxel + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01855828",
            "title": "Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1550,
                    "therapyName": "Cyclophosphamide + Epirubicin + Fluorouracil + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01873833",
            "title": "Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1559,
                    "therapyName": "Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01875666",
            "title": "Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1414,
                    "therapyName": "Lapatinib + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 856,
                    "therapyName": "Pertuzumab",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01901146",
            "title": "Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac)",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1087,
                    "therapyName": "Cyclophosphamide + Epirubicin",
                    "synonyms": null
                },
                {
                    "id": 1551,
                    "therapyName": "Paclitaxel + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01904903",
            "title": "Cardiac Safety Study in Patients With HER2+ Breast Cancer (SAFE-HEaRt)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 856,
                    "therapyName": "Pertuzumab",
                    "synonyms": null
                },
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01912963",
            "title": "Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 728,
                    "therapyName": "Eribulin",
                    "synonyms": null
                },
                {
                    "id": 856,
                    "therapyName": "Pertuzumab",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01921335",
            "title": "Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1560,
                    "therapyName": "Trastuzumab + Tucatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01922921",
            "title": "Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 8259,
                    "therapyName": "HER-2/neu intracellular domain protein  + Pertuzumab + Polysaccharide-K + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 8258,
                    "therapyName": "HER-2/neu intracellular domain protein  + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01924351",
            "title": "HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT01934894",
            "title": "Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1572,
                    "therapyName": "Cabazitaxel + Lapatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01937117",
            "title": "Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01966471",
            "title": "A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1492,
                    "therapyName": "Ado-trastuzumab emtansine + Pertuzumab",
                    "synonyms": null
                },
                {
                    "id": 1978,
                    "therapyName": "Docetaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01976169",
            "title": "Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1731,
                    "therapyName": "Ado-trastuzumab emtansine + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01983501",
            "title": "A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1573,
                    "therapyName": "Ado-trastuzumab emtansine + Tucatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01989676",
            "title": "A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin\u00ae [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1551,
                    "therapyName": "Paclitaxel + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 8261,
                    "therapyName": "Paclitaxel + PF-05280014",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02000596",
            "title": "Trastuzmab and Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1911,
                    "therapyName": "Anastrozole + Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02003209",
            "title": "Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8262,
                    "therapyName": "Carboplatin + Docetaxel + Goserelin + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1879,
                    "therapyName": "Carboplatin + Docetaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02014909",
            "title": "A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2054,
                    "therapyName": "CDX-3379",
                    "synonyms": null
                },
                {
                    "id": 2063,
                    "therapyName": "CDX-3379 + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 2064,
                    "therapyName": "CDX-3379 + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 2061,
                    "therapyName": "CDX-3379 + Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 2062,
                    "therapyName": "CDX-3379 + Erlotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02025192",
            "title": "A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3340,
                    "therapyName": "Capecitabine + Trastuzumab + Tucatinib",
                    "synonyms": null
                },
                {
                    "id": 1560,
                    "therapyName": "Trastuzumab + Tucatinib",
                    "synonyms": null
                },
                {
                    "id": 1577,
                    "therapyName": "Capecitabine + Tucatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02038010",
            "title": "BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1575,
                    "therapyName": "Ado-trastuzumab emtansine + Alpelisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02060253",
            "title": "Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1579,
                    "therapyName": "Ganetespib + Paclitaxel + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02061332",
            "title": "DC Vaccine for Patients With Ductal Carcinoma In Situ",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 5222,
                    "therapyName": "HER2-pulsed DC1 vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02063724",
            "title": "HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (Adjuvant)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5222,
                    "therapyName": "HER2-pulsed DC1 vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02066532",
            "title": "Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1578,
                    "therapyName": "Ruxolitinib + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02073487",
            "title": "Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1583,
                    "therapyName": "Ado-trastuzumab emtansine + Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 1414,
                    "therapyName": "Lapatinib + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02073916",
            "title": "TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1907,
                    "therapyName": "Ado-trastuzumab emtansine + Lapatinib + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02091960",
            "title": "A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) and Estrogen Receptor Negative (ER-) Metastatic or Locally Advanced Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1878,
                    "therapyName": "Enzalutamide + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02131064",
            "title": "A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1492,
                    "therapyName": "Ado-trastuzumab emtansine + Pertuzumab",
                    "synonyms": null
                },
                {
                    "id": 1879,
                    "therapyName": "Carboplatin + Docetaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02132949",
            "title": "A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1495,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1895,
                    "therapyName": "Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02139358",
            "title": "Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1592,
                    "therapyName": "Gemcitabine + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02152943",
            "title": "Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1591,
                    "therapyName": "Everolimus + Letrozole + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02154529",
            "title": "Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1880,
                    "therapyName": "Trastuzumab + XL647",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02167854",
            "title": "Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2059,
                    "therapyName": "Alpelisib + LJM716 + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02187744",
            "title": "A Study Of PF-05280014 Or Trastuzumab Plus Taxotere&#174; And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1485,
                    "therapyName": "Carboplatin + Docetaxel + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02213042",
            "title": "Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1414,
                    "therapyName": "Lapatinib + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02213744",
            "title": "MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1890,
                    "therapyName": "Trastuzumab + Vinorelbine",
                    "synonyms": null
                },
                {
                    "id": 1409,
                    "therapyName": "Capecitabine + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1889,
                    "therapyName": "Gemcitabine + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1888,
                    "therapyName": "MM-302 + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02229149",
            "title": "Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1685,
                    "therapyName": "Vinorelbine",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02236000",
            "title": "A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1906,
                    "therapyName": "Ado-trastuzumab emtansine + Neratinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02252887",
            "title": "Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab-Based Therapy, TDM-1, and TDM-1 + Pertuzumab",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1592,
                    "therapyName": "Gemcitabine + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02297230",
            "title": "Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1551,
                    "therapyName": "Paclitaxel + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02297698",
            "title": "Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1873,
                    "therapyName": "Sargramostim",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 3766,
                    "therapyName": "E75",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02308020",
            "title": "A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02318901",
            "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1909,
                    "therapyName": "Ado-trastuzumab emtansine + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1908,
                    "therapyName": "Pembrolizumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1910,
                    "therapyName": "Cetuximab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02326974",
            "title": "T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1492,
                    "therapyName": "Ado-trastuzumab emtansine + Pertuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02336984",
            "title": "A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 5222,
                    "therapyName": "HER2-pulsed DC1 vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02345772",
            "title": "Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 1978,
                    "therapyName": "Docetaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02390427",
            "title": "Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 856,
                    "therapyName": "Pertuzumab",
                    "synonyms": null
                },
                {
                    "id": 1016,
                    "therapyName": "Taselisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02400476",
            "title": "A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 828,
                    "therapyName": "Neratinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02402712",
            "title": "Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1978,
                    "therapyName": "Docetaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02403271",
            "title": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2573,
                    "therapyName": "Durvalumab + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02492711",
            "title": "Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1685,
                    "therapyName": "Vinorelbine",
                    "synonyms": null
                },
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 728,
                    "therapyName": "Eribulin",
                    "synonyms": null
                },
                {
                    "id": 808,
                    "therapyName": "MGAH22",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02500199",
            "title": "Open Label Oral Use of Pyrotinib in Patients With HER2 Positive Solid Tumors Who Failed Prior HER2 Targeted Therapy",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3082,
                    "therapyName": "Pyrotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02536339",
            "title": "Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02571530",
            "title": "Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02598427",
            "title": "Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02605915",
            "title": "Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3250,
                    "therapyName": "Atezolizumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 856,
                    "therapyName": "Pertuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02614794",
            "title": "Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3340,
                    "therapyName": "Capecitabine + Trastuzumab + Tucatinib",
                    "synonyms": null
                },
                {
                    "id": 1409,
                    "therapyName": "Capecitabine + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02649686",
            "title": "Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4218,
                    "therapyName": "Durvalumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02650752",
            "title": "Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1399,
                    "therapyName": "Capecitabine + Lapatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02654119",
            "title": "Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1898,
                    "therapyName": "Cyclophosphamide + Paclitaxel + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02657343",
            "title": "An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 790,
                    "therapyName": "Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02658084",
            "title": "Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3429,
                    "therapyName": "Ado-trastuzumab emtansine + Vinorelbine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02659514",
            "title": "Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1042,
                    "therapyName": "Poziotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02673398",
            "title": "Neratinib in Treating Older Patients With Locally Advanced or Metastatic HER2-Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 828,
                    "therapyName": "Neratinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02675231",
            "title": "A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (monarcHER)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 2259,
                    "therapyName": "Abemaciclib + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 8252,
                    "therapyName": "Abemaciclib + Fulvestrant + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02689921",
            "title": "NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 633,
                    "therapyName": "Anastrozole",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                },
                {
                    "id": 795,
                    "therapyName": "Leuprolide",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 738,
                    "therapyName": "Exemestane",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02774681",
            "title": "Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02789657",
            "title": "BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4235,
                    "therapyName": "Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02827877",
            "title": "Copper (Cu) 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02892123",
            "title": "Trial of ZW25 in Patients With Advanced HER2-expressing Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8332,
                    "therapyName": "Capecitabine + ZW25",
                    "synonyms": null
                },
                {
                    "id": 6240,
                    "therapyName": "ZW25",
                    "synonyms": null
                },
                {
                    "id": 8333,
                    "therapyName": "Paclitaxel + ZW25",
                    "synonyms": null
                },
                {
                    "id": 8334,
                    "therapyName": "Vinorelbine + ZW25",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02907918",
            "title": "Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (PALTAN)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 759,
                    "therapyName": "Goserelin",
                    "synonyms": null
                },
                {
                    "id": 4756,
                    "therapyName": "Letrozole + Palbociclib + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02924883",
            "title": "A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy (KATE2)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 3250,
                    "therapyName": "Atezolizumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02947685",
            "title": "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 856,
                    "therapyName": "Pertuzumab",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                },
                {
                    "id": 633,
                    "therapyName": "Anastrozole",
                    "synonyms": null
                },
                {
                    "id": 738,
                    "therapyName": "Exemestane",
                    "synonyms": null
                },
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03054363",
            "title": "Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5334,
                    "therapyName": "Letrozole + Palbociclib + Tucatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03112590",
            "title": "Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5548,
                    "therapyName": "interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03125928",
            "title": "Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5600,
                    "therapyName": "Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03135171",
            "title": "Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5648,
                    "therapyName": "Pertuzumab + Tocilizumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03155997",
            "title": "Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03190967",
            "title": "T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                },
                {
                    "id": 5932,
                    "therapyName": "Ado-trastuzumab emtansine + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03284723",
            "title": "PF-06804103 Dose Escalation in HER2 Positive Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7359,
                    "therapyName": "PF-06804103",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03304080",
            "title": "Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6323,
                    "therapyName": "Anastrozole + Palbociclib + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03319459",
            "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6375,
                    "therapyName": "FATE-NK100",
                    "synonyms": null
                },
                {
                    "id": 6376,
                    "therapyName": "FATE-NK100 + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 6377,
                    "therapyName": "Cetuximab + FATE-NK100",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03321981",
            "title": "MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6385,
                    "therapyName": "Letrozole + MCLA-128",
                    "synonyms": null
                },
                {
                    "id": 6386,
                    "therapyName": "Anastrozole + MCLA-128",
                    "synonyms": null
                },
                {
                    "id": 6383,
                    "therapyName": "Fulvestrant + MCLA-128",
                    "synonyms": null
                },
                {
                    "id": 6384,
                    "therapyName": "Exemestane + MCLA-128",
                    "synonyms": null
                },
                {
                    "id": 6381,
                    "therapyName": "MCLA-128 + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 6382,
                    "therapyName": "MCLA-128 + Trastuzumab + Vinorelbine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03324425",
            "title": "Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer (SIMPHONY)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2239,
                    "therapyName": "Simvastatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03329378",
            "title": "Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6435,
                    "therapyName": "Docetaxel + Paclitaxel + Pegfilgrastim + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 6434,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03330561",
            "title": "PRS-343 in HER2-Positive Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6437,
                    "therapyName": "PRS-343",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03364348",
            "title": "4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6500,
                    "therapyName": "Trastuzumab + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 6499,
                    "therapyName": "Ado-trastuzumab emtansine + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03368729",
            "title": "Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6523,
                    "therapyName": "Niraparib + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03377387",
            "title": "Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1543,
                    "therapyName": "Capecitabine + Neratinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03379428",
            "title": "Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 6531,
                    "therapyName": "Ibrutinib + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03384914",
            "title": "Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5222,
                    "therapyName": "HER2-pulsed DC1 vaccine",
                    "synonyms": null
                },
                {
                    "id": 9734,
                    "therapyName": "pUMVC3-IGFBP2-HER2-IGF1R vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03387553",
            "title": "HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5222,
                    "therapyName": "HER2-pulsed DC1 vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03414658",
            "title": "The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6668,
                    "therapyName": "Avelumab + Trastuzumab + Utomilumab + Vinorelbine",
                    "synonyms": null
                },
                {
                    "id": 6667,
                    "therapyName": "Avelumab + Trastuzumab + Vinorelbine",
                    "synonyms": null
                },
                {
                    "id": 6669,
                    "therapyName": "Avelumab + Trastuzumab + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 1890,
                    "therapyName": "Trastuzumab + Vinorelbine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03417544",
            "title": "Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6656,
                    "therapyName": "Atezolizumab + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03429101",
            "title": "A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 6799,
                    "therapyName": "Ado-trastuzumab emtansine + Poziotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03433313",
            "title": "Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7765,
                    "therapyName": "Cyclophosphamide + Epirubicin + Paclitaxel + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 7764,
                    "therapyName": "Cyclophosphamide + EG12014 + Epirubicin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03451162",
            "title": "Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6872,
                    "therapyName": "DHES0815A",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03493854",
            "title": "A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 6434,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03501979",
            "title": "Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3340,
                    "therapyName": "Capecitabine + Trastuzumab + Tucatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03521245",
            "title": "Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03523585",
            "title": "DS-8201a Versus Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Pretreated With Prior Standard of Care",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4844,
                    "therapyName": "Fam-trastuzumab deruxtecan-nxki",
                    "synonyms": null
                },
                {
                    "id": 1399,
                    "therapyName": "Capecitabine + Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 1409,
                    "therapyName": "Capecitabine + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03529110",
            "title": "DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4844,
                    "therapyName": "Fam-trastuzumab deruxtecan-nxki",
                    "synonyms": null
                },
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03530696",
            "title": "T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer (T-DM1)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                },
                {
                    "id": 1731,
                    "therapyName": "Ado-trastuzumab emtansine + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03587740",
            "title": "ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03620201",
            "title": "M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5860,
                    "therapyName": "M7824",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03630809",
            "title": "Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5222,
                    "therapyName": "HER2-pulsed DC1 vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03674112",
            "title": "A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03709082",
            "title": "Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7439,
                    "therapyName": "Ado-trastuzumab emtansine + Letrozole + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03716180",
            "title": "DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03726879",
            "title": "A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 7560,
                    "therapyName": "Atezolizumab + Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 5600,
                    "therapyName": "Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 6656,
                    "therapyName": "Atezolizumab + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03747120",
            "title": "Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5956,
                    "therapyName": "Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 7583,
                    "therapyName": "Paclitaxel + Pembrolizumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03765983",
            "title": "GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7612,
                    "therapyName": "GDC-0084 + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03846583",
            "title": "Tucatinib + Abemaciclib + Herceptin for HER2+ MBC",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 7907,
                    "therapyName": "Abemaciclib + Trastuzumab + Tucatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03975647",
            "title": "A Study of Tucatinib vs. Placebo in Combination With Trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1573,
                    "therapyName": "Ado-trastuzumab emtansine + Tucatinib",
                    "synonyms": null
                },
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03983395",
            "title": "Study of GBR 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8171,
                    "therapyName": "GBR1302",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04042701",
            "title": "DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9315,
                    "therapyName": "Fam-trastuzumab deruxtecan-nxki + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04054752",
            "title": "Vaccine Response With NT-I7",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9320,
                    "therapyName": "NT-I7",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04120246",
            "title": "Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8835,
                    "therapyName": "alpha-TEA + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04147819",
            "title": "A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9606,
                    "therapyName": "BAY2701439",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04224272",
            "title": "A Study of ZW25 With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9245,
                    "therapyName": "Fulvestrant + Palbociclib + ZW25",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04266249",
            "title": "CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1549,
                    "therapyName": "Paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                },
                {
                    "id": 1978,
                    "therapyName": "Docetaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 8163,
                    "therapyName": "Nab-paclitaxel + Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04296942",
            "title": "BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 6892,
                    "therapyName": "FPV-Brachyury + M7824 + MVA-BN-Brachyury",
                    "synonyms": null
                },
                {
                    "id": 9464,
                    "therapyName": "Ado-trastuzumab emtansine + Entinostat + FPV-Brachyury + M7824 + MVA-BN-Brachyury",
                    "synonyms": null
                },
                {
                    "id": 9463,
                    "therapyName": "Ado-trastuzumab emtansine + FPV-Brachyury + M7824 + MVA-BN-Brachyury",
                    "synonyms": null
                }
            ]
        }
    ]
}